Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA clarification that OTC ephedrine proposal exempts ephedra requested in comments.

This article was originally published in The Tan Sheet

Executive Summary

FDA CLARIFICATION THAT OTC EPHEDRINE PROPOSAL DOES NOT EXTEND TO EPHEDRA REQUESTED in Sept. 27 comments submitted to the agency by a group involved in the marketing of ephedra herb tea. "Because an indiscriminate determination that all ephedrine is not GRAS would adversely affect the joint commenters' economic interests and their opportunity to continue marketing and consuming ephedra herb tea," the comments state, "they...feel compelled to request that the agency make clear that it does not intend for its final rule to affect ephedra herb food or dietary supplements."

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS084390

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel